GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
NCT07021209 is a phase 1 interventional trial sponsored by Grit Biotechnology. As of 18 Nov 2026, it is recruiting participants. It studies GT719 Injection in Neurological Autoimmune Diseases. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 14 Jan 2025 and a primary completion date of 13 Jan 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07021209 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Grit Biotechnology |
| Enrollment | 30 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Neurological Autoimmune Diseases |
| Drugs | GT719 Injection |
| Start | 14 Jan 2025 |
| Primary completion | 13 Jan 2028 |
| Study completion | 13 Jan 2028 |
| Last update posted | 11 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Chuan Qin
Tongji Hospital
Principal Investigator - Daishi Tian
Tongji Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tongji Hospital Affiliated To Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei
Recruiting
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07021209
Each answer restates registry values shown on this page.
What is NCT07021209?
NCT07021209 is a phase 1 interventional trial sponsored by Grit Biotechnology. It studies GT719 Injection in Neurological Autoimmune Diseases.
Is NCT07021209 recruiting?
As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT07021209?
The registry names Chuan Qin (principal investigator, Tongji Hospital), Daishi Tian (principal investigator, Tongji Hospital) and Wei Wang (principal investigator, Tongji Hospital) as overall officials.
Where does NCT07021209 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.
Which drugs does NCT07021209 study?
The registered drug and biological interventions are GT719 Injection.
When is NCT07021209 expected to complete?
The registry lists a primary completion date of 13 Jan 2028 and a study completion date of 13 Jan 2028. The sponsor last updated the record on 11 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.